• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质母细胞瘤手术与辅助治疗期间的早期 MRI 变化。

Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy.

机构信息

Anatomy and Histology Section, Department of Morphological and Biomedical Sciences, University of Verona, Via Le Grazie 8, 37134 Verona, VR, Italy.

出版信息

J Neurooncol. 2013 Jan;111(2):177-85. doi: 10.1007/s11060-012-0997-y. Epub 2012 Dec 22.

DOI:10.1007/s11060-012-0997-y
PMID:23264191
Abstract

To investigate the increase in MRI contrast enhancement (CE) occurring in glioblastoma during the period between surgery and initiation of chemo-radiotherapy, thirty-seven patients with newly diagnosed glioblastoma were analyzed by early post-operative magnetic resonance (EPMR) imaging within three days of surgery and by pre-adjuvant magnetic resonance (PAMR) examination before adjuvant therapy. Areas of new CE were investigated by use of EPMR diffusion-weighted imaging and PAMR perfusion imaging (by arterial spin-labeling). PAMR was acquired, on average, 29.9 days later than EPMR (range 20-37 days). During this period an increased area of CE was observed for 17/37 patients. For 3/17 patients these regions were confined to areas of reduced EPMR diffusion, suggesting postsurgical infarct. For the other 14/17 patients, these areas suggested progression. For 11/17 patients the co-occurrence of hyperperfusion in PAMR perfusion suggested progression. PAMR perfusion and EPMR diffusion did not give consistent results for 3/17 patients for whom small new areas of CE were observed, presumably because of the poor spatial resolution of perfusion imaging. Before initiation of adjuvant therapy, areas of new CE of resected glioblastomas are frequently observed. Most of these suggest tumor progression, according to EPMR diffusion and PAMR perfusion criteria.

摘要

为了研究在手术和放化疗开始之间,脑胶质瘤患者的磁共振成像(MRI)增强(CE)的增加,对 37 例新诊断的脑胶质瘤患者进行了分析,这些患者在手术后 3 天内进行了早期术后磁共振成像(EPMR)检查,并在辅助治疗前进行了预辅助磁共振成像(PAMR)检查。通过 EPMR 弥散加权成像和 PAMR 灌注成像(动脉自旋标记)研究了新 CE 区域。PAMR 的采集时间平均比 EPMR 晚 29.9 天(范围 20-37 天)。在此期间,观察到 17/37 例患者的 CE 区域增加。对于 3/17 例患者,这些区域局限于 EPMR 弥散降低的区域,提示术后梗死。对于其他 14/17 例患者,这些区域提示进展。对于 11/17 例患者,PAMR 灌注中的高灌注提示进展。对于 3/17 例患者,由于灌注成像的空间分辨率较差,观察到小的新 CE 区域,PAMR 灌注和 EPMR 弥散的结果不一致。在开始辅助治疗之前,经常观察到切除的脑胶质瘤的新 CE 区域。根据 EPMR 弥散和 PAMR 灌注标准,这些区域中的大多数提示肿瘤进展。

相似文献

1
Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy.胶质母细胞瘤手术与辅助治疗期间的早期 MRI 变化。
J Neurooncol. 2013 Jan;111(2):177-85. doi: 10.1007/s11060-012-0997-y. Epub 2012 Dec 22.
2
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.新诊断为胶质母细胞瘤的患者在手术和辅助治疗开始之间的肿瘤复发。
Neuro Oncol. 2009 Dec;11(6):842-52. doi: 10.1215/15228517-2009-005.
3
Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients.胶质母细胞瘤术后早期磁共振成像:60例患者放射学表现与总生存期的相关性
Eur Radiol. 2016 Apr;26(4):1048-55. doi: 10.1007/s00330-015-3914-x. Epub 2015 Jul 19.
4
Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.神经肿瘤学中的疗效评估标准、对比增强及灌注MRI用于评估胶质母细胞瘤的进展情况。
Neuroradiology. 2017 Oct;59(10):1013-1020. doi: 10.1007/s00234-017-1899-7. Epub 2017 Aug 25.
5
Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.IVIM-DWI与3D-ASL联合用于鉴别多形性胶质母细胞瘤同步放化疗后真性进展与假性进展:一项前瞻性诊断试验的研究方案
BMC Med Imaging. 2017 Feb 1;17(1):10. doi: 10.1186/s12880-017-0183-y.
6
Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.胶质母细胞瘤患者的假性进展:动脉自旋标记对比动态磁敏感对比灌注磁共振成像的附加价值
Acta Radiol. 2013 May;54(4):448-54. doi: 10.1177/0284185112474916. Epub 2013 Apr 30.
7
Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.快速早期肿瘤进展与胶质母细胞瘤患者的预后相关。
Am J Clin Oncol. 2019 May;42(5):481-486. doi: 10.1097/COC.0000000000000537.
8
Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.动脉自旋标记灌注加权成像有助于预测胶质母细胞瘤的分子生物标志物和生存。
Eur Radiol. 2020 Feb;30(2):1202-1211. doi: 10.1007/s00330-019-06379-2. Epub 2019 Aug 29.
9
Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.在预测新诊断胶质母细胞瘤的生存率方面,临床参数比基于扩散和灌注的MRI参数更为重要。
Neuro Oncol. 2016 Dec;18(12):1673-1679. doi: 10.1093/neuonc/now122. Epub 2016 Jun 13.
10
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.在辅助治疗前对新诊断的胶质母细胞瘤患者中预测生存的磁共振成像(MR)标志物进行评估。
J Neurooncol. 2009 Jan;91(1):69-81. doi: 10.1007/s11060-008-9685-3. Epub 2008 Sep 23.

引用本文的文献

1
Advances of MR imaging in glioma: what the neurosurgeon needs to know.磁共振成像在胶质瘤中的进展:神经外科医生需要了解的内容。
Acta Neurochir (Wien). 2025 Jun 21;167(1):174. doi: 10.1007/s00701-025-06593-6.
2
C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET).C-蛋氨酸在快速早期进展型胶质母细胞瘤患者诊断和治疗中的应用:非随机、开放标签、前瞻性临床试验(Gliomet)。
BMC Cancer. 2024 Jun 15;24(1):736. doi: 10.1186/s12885-024-12469-2.
3
Adoption of Hybrid MRI-Linac Systems for the Treatment of Brain Tumors: A Systematic Review of the Current Literature Regarding Clinical and Technical Features.

本文引用的文献

1
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.手术后无或仅有少量残留增强肿瘤负荷的胶质母细胞瘤患者同步和辅助替莫唑胺放化疗的前瞻性队列研究。
J Neurooncol. 2012 May;108(1):89-97. doi: 10.1007/s11060-012-0798-3. Epub 2012 Feb 4.
2
Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?胶质母细胞瘤放疗时机的延迟:把治疗提前(或推后)到优先队列有多重要?
J Neurooncol. 2011 Oct;105(1):1-7. doi: 10.1007/s11060-011-0589-2. Epub 2011 Apr 24.
3
混合动力 MRI-直线加速器系统在脑肿瘤治疗中的应用:当前文献中关于临床和技术特征的系统评价。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231199286. doi: 10.1177/15330338231199286.
4
Prediction of Rapid Early Progression and Survival Risk with Pre-Radiation MRI in WHO Grade 4 Glioma Patients.基于放疗前MRI对世界卫生组织4级胶质瘤患者早期快速进展和生存风险的预测
Cancers (Basel). 2023 Sep 19;15(18):4636. doi: 10.3390/cancers15184636.
5
Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.高级磁共振成像在治疗后胶质母细胞瘤评估中的应用:图文综述
Cancers (Basel). 2023 Jul 26;15(15):3790. doi: 10.3390/cancers15153790.
6
Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study.再次手术时机对复发性胶质母细胞瘤患者生存的影响:一项回顾性多中心描述性研究
Cancers (Basel). 2023 Apr 28;15(9):2530. doi: 10.3390/cancers15092530.
7
Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma.异柠檬酸脱氢酶野生型胶质母细胞瘤手术与放疗之间,对比增强和非对比增强肿瘤区域的MRI体积变化的频率及预后相关性
Cancers (Basel). 2023 Mar 14;15(6):1745. doi: 10.3390/cancers15061745.
8
Comparison of EPI DWI and STEAM DWI in Early Postoperative MRI Controls After Resection of Tumors of the Central Nervous System.中枢神经系统肿瘤切除术后早期 MRI 复查中 EPI DWI 与 STEAM DWI 的对比研究。
Clin Neuroradiol. 2023 Sep;33(3):677-685. doi: 10.1007/s00062-023-01261-7. Epub 2023 Feb 2.
9
Challenges and opportunities for advanced neuroimaging of glioblastoma.胶质母细胞瘤的高级神经影像学的挑战与机遇。
Br J Radiol. 2023 Jan 1;96(1141):20211232. doi: 10.1259/bjr.20211232. Epub 2022 Oct 14.
10
Volumetric and dosimetric impact of post-surgical MRI-guided radiotherapy for glioblastoma: A pilot study.胶质母细胞瘤术后MRI引导下放疗的容积和剂量学影响:一项试点研究。
BJR Open. 2021 Nov 26;3(1):20210067. doi: 10.1259/bjro.20210067. eCollection 2021.
Baseline preadjuvant magnetic resonance imaging for response assessment and for planning radiotherapy in glioblastoma.
J Clin Oncol. 2011 Feb 20;29(6):e148; author reply e149. doi: 10.1200/JCO.2010.32.9888. Epub 2010 Dec 28.
4
Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.脑胶质瘤的临床靶区勾画:术前与术后/放疗前 MRI 比较。
Br J Radiol. 2011 Mar;84(999):271-8. doi: 10.1259/bjr/10315979. Epub 2010 Nov 2.
5
DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma.弥散张量成像和灌注加权成像分析胶质母细胞瘤治疗后瘤周强化脑组织。
J Neurooncol. 2011 Apr;102(2):261-71. doi: 10.1007/s11060-010-0310-x. Epub 2010 Jul 25.
6
Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.使用 Ferumoxytol 与 Gadoteridol 行动态磁敏感对比增强磁共振成像对假性进展与真性肿瘤进展的鉴别潜能:一项初步研究。
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):514-23. doi: 10.1016/j.ijrobp.2009.10.072. Epub 2010 Apr 13.
7
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.参数响应图作为一种成像生物标志物,可区分高级别胶质瘤的进展与假性进展。
J Clin Oncol. 2010 May 1;28(13):2293-9. doi: 10.1200/JCO.2009.25.3971. Epub 2010 Apr 5.
8
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准:神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
9
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.采用动态磁敏感加权对比增强灌注磁共振成像鉴别多形性胶质母细胞瘤复发与外照射放疗后放射性坏死
Radiology. 2009 Nov;253(2):486-96. doi: 10.1148/radiol.2532090007. Epub 2009 Sep 29.
10
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.胶质瘤的终点评估:新型治疗方法限制了经典麦克唐纳标准的实用性。
J Clin Oncol. 2009 Jun 20;27(18):2905-8. doi: 10.1200/JCO.2009.22.4998. Epub 2009 May 18.